三联抗病毒方案在HIV-1感染治疗中的地位和作用

Role of triple therapy in the treatment of HIV-1 infection

1型艾滋病病毒(HIV-1)感染者抗病毒治疗(ART)中,包含两种药物类别的三联疗法同时作用于多个靶点,耐药屏障高,可持久抑制病毒,因此一直是HIV感染的标准治疗策略。评估开发新的两联方案已经成为近年来抗HIV治疗方案优化的研究方向之一。这一治疗思路与标准三联疗法相比,疗效持久性、诱发耐药风险及适用范围如何,是艾滋病抗病毒治疗领域关心的问题。本文对两联治疗方案的研究进展做一综述,并通过与三联方案的比较,阐述三联疗法在当前抗HIV治疗中的地位和作用。

The triple antiretroviral therapy(ART) for people infected with HIV-1 has been the standard treatment, which can simultaneously act to multiple-targets, and have durable viral suppression and low emergence of resistance. However, the development of the simplified dual ART has been a research hotspot in recent years. The relative value of the dual therapy compared to that of the triple therapy would depend on durability of virological response, risk of resistance, and eligibility in different HIV-infected patients. This article reviews the development in the research of the dual therapy for HIV infection by comparison with the triple therapy, to illustrate the role of the latter in the treatment of HIV infection.